Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Reimer, Peter ^a   Chawla, Shanta ^b  

^a Internistische Onkologie und Stammzelltransplantation   (Germany)

^b Spectrum Pharmaceuticals   (United States)

Author keywords

Belinostat; HDAC inhibitor; Peripheral T cell lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METRONIDAZOLE; PREDNISOLONE; STEROID; VINCRISTINE; VORICONAZOLE;

AGED; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CERVICAL LYMPHADENOPATHY; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOARSENESS; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LONG TERM CARE; LUNG ALVEOLITIS; LUNG MYCOSIS; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; PERIPHERAL T CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA NOT OTHERWISE SPECIFIED; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, PERIPHERAL; PROGNOSIS; REMISSION INDUCTION; SULFONAMIDES;

EID: 84883620467     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-69     Document Type: Article

References (12)

1. Peripheral T-cell lymphomas: clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ascani S, Zinzani PL, Gherlinzoni F, Sabattini E, Briskomatis A, de Vivo A, Piccioli M, Fraternali Orcioni G, Pieri F, Goldoni A, Piccaluga PP, Zallocco D, Burnelli R, Leoncini L, Falini B, Tura S, Pileri SA, Ann Oncol 1997 8 583 592 10.1023/A:1008200307625 9261528
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project. Anonymous, Blood 1997 89 3909 3918 9166827
3. Non-Hodgkin's Lymphoma Classification Project: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Ullrich F, Müller-Hermelink HK, Ann Oncol 2002 13 140 149 10.1093/annonc/mdf033 11863096
4. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J, Ann Oncol 1990 1 45 50 1706610
5. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Armitage J, Vose JM, Weisenburger D, J Clin Oncol 2008 26 4124 4130 18626005
6. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A, Weisenburger DD, Blood 1999 93 3913 3921 10339500
7. ALK + lymphoma: clinico-pathological findings and outcome. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF, Santucci A, Blood 1999 93 2697 2706 10194450
8. Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen. Huang HQ, Peng YL, Lin XB, Sun XF, Lin TY, Xia ZJ, Li YH, Cai QQ, He YJ, Jiang WQ, Guan ZZ, Ai Zheng 2004 23 suppl 11 1443 1447 15566653
9. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Kim K, Kim WS, Jung CW, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K, et al. Eur J Cancer 2002 38 75 81 11750843
10. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. López-Guillermo A, Cid J, Salar A, López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, González M, Ribera JM, Brunet S, García-Conde J, de Fernández Sevilla A, Bosch F, Montserrat E, et al. Ann Oncol 1998 9 849 855 10.1023/A:1008418727472 9789607
11. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abtract]. Pohlman B, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Ben-Yehuda D, Beylot-Barry M, Hillen U, Fagerberg J, Foss FM, Blood 2009 114 22 379
12. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial [abtract]. O'Connor OA, Masszi T, Savage KJ, Pinter-Brown LC, Foss FM, Popplewell L, Cashen AF, Doorduijn J, Chawla S, Knoblauch P, Zinzani PL, Brown P, Hess G, Van Hoof A, Horwitz SM, Shustov AR, J Clin Oncol 2013 31 850